Trade Name

Target

Manufacturer

Indications

Adcetris (brentuximab vedotin)

CD30

Takeda / Seagen

Hodgkin lymphoma, anaplastic large cell lymphoma [9]

Kadcyla (trastuzumab emtansine)

HER2

Roche / Genentech

HER2-positive breast cancer [10]

Besponsa (inotuzumab ozogamicin)

CD22

Pfizer / Wyeth

Acute lymphoblastic leukemia (B-ALL) [11]

Mylotarg (gemtuzumab ozogamicin)

CD33

Pfizer / Wyeth

Acute myeloid leukemia (AML) [12]

Lumoxiti (moxetumomab pasudotox)

CD22

AstraZeneca

Hairy cell leukemia [13]

Polivy (polatuzumab vedotin)

CD79b

Roche / Genentech

Diffuse large B-cell lymphoma [14]

Padcev (enfortumab vedotin)

Nectin-4

Astellas / Seagen

Urothelial carcinoma (bladder cancer) [15]

Enhertu (fam-trastuzumab deruxtecan-nxki)

HER2

Daiichi Sankyo / AstraZeneca

HER2-positive and HER2-low breast cancer, gastric cancer [16]

Trodelvy (sacituzumab govitecan)

TROP-2

Gilead / Immunomedics

Triple-negative breast cancer, urothelial carcinoma [17]

Blenrep (belantamab mafodotin)

BCMA

GSK

Multiple myeloma [18]

Zynlonta (loncastuximab tesirine)

CD19

Sobi / ADC Therapeutics

Diffuse large B-cell lymphoma [19]

Tivdak (tisotumab vedotin-tftv)

Tissue Factor

Seagen / Genmab

Cervical cancer [20]

Akalux (cetuximab sarotalocan)

EGFR

Rakuten Medical

Head and neck squamous cell carcinoma (Japan only) [21]

Elahere (mirvetuximab soravtansine)

Folate Receptor α (FRα)

ImmunoGen

Ovarian cancer (FRα-positive) [22]

Vyloy (telisotuzumab vedotin)

B7-H3

Y-mAbs Therapeutics

Neuroblastoma (pediatric, USA only) [23]

Aidixi (disitamab vedotin)

HER2

RemeGen

 Breast cancer (approved in China) [24]